Order Article Reprints

Song Y, Pan S, Tian J, Yu Y, Wang S, Qiu Q, Shen Y, Yang L, Liu X, Luan J, et al. Activation of CD14+ Monocytes via the IFN-γ Signaling Pathway Is Associated with Immune-Related Adverse Events in Hepatocellular Carcinoma Patients Receiving PD-1 Inhibition Combination Therapy. Biomedicines. 2024; 12(6):1140. https://doi.org/10.3390/biomedicines12061140

Song, Yaoru, Shida Pan, Jiahe Tian, Yingying Yu, Siyu Wang, Qin Qiu, Yingjuan Shen, Luo Yang, Xiaomeng Liu, Junqing Luan, and et al. 2024. "Activation of CD14+ Monocytes via the IFN-γ Signaling Pathway Is Associated with Immune-Related Adverse Events in Hepatocellular Carcinoma Patients Receiving PD-1 Inhibition Combination Therapy" Biomedicines 12, no. 6: 1140. https://doi.org/10.3390/biomedicines12061140

Song, Y., Pan, S., Tian, J., Yu, Y., Wang, S., Qiu, Q., Shen, Y., Yang, L., Liu, X., Luan, J., Wang, Y., Wang, J., Fan, X., Meng, F., & Wang, F.-S. (2024). Activation of CD14+ Monocytes via the IFN-γ Signaling Pathway Is Associated with Immune-Related Adverse Events in Hepatocellular Carcinoma Patients Receiving PD-1 Inhibition Combination Therapy. Biomedicines, 12(6), 1140. https://doi.org/10.3390/biomedicines12061140